Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
5,085 studies for “Novartis”
Sponsor: Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya +2 more
Sponsor: Novartis Pharmaceuticals
Uncomplicated Plasmodium Falciparum Malaria
Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya +2 more
- A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.Active Not Recruiting
Sponsor: Novartis Pharmaceuticals
Glioblastoma
United States, France, Portugal, Spain, Switzerland
Sponsor: Novartis Pharmaceuticals
Triple Negative Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +25 more
Sponsor: Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
United States
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
United States, Argentina, Austria, Belgium, Brazil +14 more
- Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid DiseasesActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Myeloid Diseases
United States, France, Germany, Hong Kong, Italy +3 more
- Specified Drug-use Surveillance of Fabhalta CapsulesActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Paroxysmal Nocturnal Hemoglobinuria
Japan
Sponsor: Novartis Pharmaceuticals
Heart Failure With Reduced Ejection Fraction
United States, Canada
- Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive Not Recruiting
Sponsor: Novartis Pharmaceuticals
Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (Post-PV MF) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Japan
Sponsor: Novartis Pharmaceuticals
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer · Advanced Solid Tumors Harboring the KRAS G12C Mutation
Belgium, Canada, China, Denmark, France +5 more
- A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell DiseaseRecruiting
Sponsor: Novartis Pharmaceuticals
Sickle Cell Disease
United States, Turkey (Türkiye)
Sponsor: Novartis Pharmaceuticals
Achilles Tendinopathy
United States, France, Germany
Sponsor: Novartis Pharmaceuticals
Sjögren´s Disease
United States, Australia, Canada, South Korea
Sponsor: Novartis Pharmaceuticals
Primary Immunoglobulin A Nephropathy (IgAN)
United States, Argentina, Australia, China, Hong Kong +3 more
Sponsor: Novartis Pharmaceuticals
Advanced Gastroesophageal Adenocarcinoma · Advanced Breast Cancer · Triple-negative Breast Cancer · Advanced Non-small Cell Lung Cancer
Japan
Sponsor: Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP) · Primary Evans Syndrome (ES)
United States
- A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy SubjectsCompleted
Sponsor: Novartis Pharmaceuticals
Visceral Leishmaniasis · Chagas Disease
United States
Sponsor: Novartis Pharmaceuticals
Sjögren's Disease
United States, Australia, Canada, Israel
Sponsor: Novartis Pharmaceuticals
Indication of the Parent Protocol
Bulgaria, Canada, Czechia, France, Poland +3 more
Sponsor: Novartis Pharmaceuticals
Chronic Pruritus of Unknown Origin
United States, Japan
Sponsor: Novartis Pharmaceuticals
Geographic Atrophy Secondary to Age-related Macular Degeneration
United States, Australia, Bulgaria, Canada, Colombia +11 more
Sponsor: Novartis Pharmaceuticals
Juvenile Psoriatic Arthritis
United States
Sponsor: Novartis Pharmaceuticals
Lupus Nephritis
United States, Brazil, China, Colombia, Czechia +13 more
- A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic SclerosisRecruiting
Sponsor: Novartis Pharmaceuticals
Diffuse Cutaneous Systemic Sclerosis
United States, Argentina, Austria, Belgium, Brazil +20 more
5,085 studies found